These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22705799)

  • 1. Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis.
    Najera JE; Alousi A; De Lima M; Ciurea SO
    Bone Marrow Transplant; 2013 Jan; 48(1):157-8. PubMed ID: 22705799
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akinetic mutism induced by tacrolimus.
    Sierra-Hidalgo F; Martínez-Salio A; Moreno-García S; de Pablo-Fernández E; Correas-Callero E; Ruiz-Morales J
    Clin Neuropharmacol; 2009; 32(5):293-4. PubMed ID: 19820432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-sensitivity reaction between tacrolimus and macrolide antibiotics.
    Riley L; Mudd L; Baize T; Herzig R
    Bone Marrow Transplant; 2000 Apr; 25(8):907-8. PubMed ID: 10808214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
    Toledo Perdomo K; Navarro Cabello MD; Pérez Sáez MJ; Ramos Pérez MJ; Agüera Morales ML; Aljama García P
    J Nephrol; 2012; 25(5):839-42. PubMed ID: 22252846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.
    Fay JW; Wingard JR; Antin JH; Collins RH; Piñeiro LA; Blazar BR; Saral R; Bierer BE; Przepiorka D; Fitzsimmons WE; Maher RM; Weisdorf DJ
    Blood; 1996 Apr; 87(8):3514-9. PubMed ID: 8605372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children.
    Kanekiyo T; Hara J; Matsuda-Hashii Y; Fujisaki H; Tokimasa S; Sawada A; Kubota K; Shimono K; Imai K; Ozono K
    Int J Hematol; 2005 Apr; 81(3):264-8. PubMed ID: 15814339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT.
    Fuji S; Kim SW; Mori S; Furuta K; Tanosaki R; Heike Y; Takaue Y; Fukuda T
    Bone Marrow Transplant; 2010 Feb; 45(2):405-6. PubMed ID: 19648969
    [No Abstract]   [Full Text] [Related]  

  • 10. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation].
    Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K
    Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases.
    Miyakoshi S; Kami M; Tanimoto T; Yamaguchi T; Narimatsu H; Kusumi E; Matsumura T; Takagi S; Kato D; Kishi Y; Murashige N; Yuji K; Uchida N; Masuoka K; Wake A; Taniguchi S
    Transplantation; 2007 Aug; 84(3):316-22. PubMed ID: 17700155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
    Rodriguez R; Nakamura R; Palmer JM; Parker P; Shayani S; Nademanee A; Snyder D; Pullarkat V; Kogut N; Rosenthal J; Smith E; Karanes C; O'Donnell M; Krishnan AY; Senitzer D; Forman SJ
    Blood; 2010 Feb; 115(5):1098-105. PubMed ID: 19965688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.
    Mollee P; Morton AJ; Irving I; Durrant S
    Br J Haematol; 2001 Apr; 113(1):217-23. PubMed ID: 11328304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
    Przepiorka D; Devine S; Fay J; Uberti J; Wingard J
    Bone Marrow Transplant; 1999 Nov; 24(10):1053-6. PubMed ID: 10578154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case of encephalopathy seemingly caused by tacrolimus at blood concentration near the upper limit of therapeutic range].
    Yamaguchi K; Fukuoka N; Kimura S; Shinohara N; Tatsumichi T; Tai T; Kosaka S; Ohnishi H; Houchi H
    Yakugaku Zasshi; 2012; 132(7):845-8. PubMed ID: 22790031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eye Movement Disorders Following Allogeneic Bone Marrow Transplantation on FK506 (Tacrolimus) and Ganciclovir.
    Karagun BS; Akbas T; Arpaci T; Antmen B
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):71-73. PubMed ID: 28731920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.
    Przepiorka D; Ippoliti C; Khouri I; Woo M; Mehra R; Le Bherz D; Giralt S; Gajewski J; Fischer H; Fritsche H; Deisseroth AB; Cleary K; Champlin R; Besien K; Andersson B; Maher R; Fitzsimmons W
    Blood; 1996 Dec; 88(11):4383-9. PubMed ID: 8943876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.